Brain Stimulation for the Treatment of Tourette Syndrome

NCT ID: NCT01329198

Last Updated: 2018-06-08

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-09-30

Study Completion Date

2017-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this trial is to determine whether a particular type of Deep Brain Stimulation (DBS), scheduled Deep Brain stimulation (SBS), is an effective and safe treatment for Tourettte syndrome (TS).

The trial will also examine the brain activity associated with TS and tics and explore the possibility of responsive brain stimulation (RBS).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

DBS is a surgical procedure that seeks to change the brain's electrical signalling by means of applied electrical current. To this end, a wire with tiny stimulating electrodes is implanted into one or both sides of the brain. An electrode is a small piece of metal used to take an electric current to or from a power source. These electrodes are connected under the skin on the scalp to a small electrical unit called an INS (implantable neurostimulator), which is similar to a heart pacemaker. The device sends out electrical impulses that appear to change the normal flow of electricity in the brain.

The wires which house the electrodes will be implanted on both sides of the brain oriented towards the centromedian thalamus-parafascicular complex. This region of the brain has to date the greats number of documented cases revealing significant improvements in motor tics.

This region of the brain will also provide a target where physiological changes related to motor tics are likely to be discovered.

The device we propose for this study has several features that make it more suitable for use in the TS population than other devices. It is self-contained in the skull and brain, and contains no tunneled neck connector wire and no chest pacemaker deice. This will help to lessen infection, and will assist in limiting device-related fractures due to tics involving neck region. Also, the system can record electro-encephalograph data from the area of the electrodes, which will assist us in gathering information about what specific physiological changes are correlated with tics.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tourette Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Prospective blinded staggered onset design
Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors
Programming to be performed for this study by the programming investigator under the supervision of the PI

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Delayed Activation - Deep Brain Stimulation (DBS)

Delayed Activation stimulation in which no electrical charge is delivered through the Neuropace RNS (responsive neurostimulation) system for the first 59 days. On Day 60, all subjects will be programmed to receive active stimulation.

* There will be a one month post-operative period during which stimulation is not turned on.
* One month post-implant, subjects will be randomized one to one in a blinded fashion to receive active or sham stimulation.
* By Day 60, all subjects will be programmed to receive active stimulation. Physiological data will be collected for Specific Aim 2 of the study.
* Both the sham and the active groups (3 subjects in each group) will undergo identical programming procedures at 30 and 60 days.

Group Type ACTIVE_COMPARATOR

NeuroPace RNS® System Deep Brain Stimulator

Intervention Type DEVICE

Utilizes a signal that the device detects and will respond to with an electrical pre-defined pulse if the signal is encountered.

Immediate Activation - Deep Brain Stimulation (DBS)

Active stimulation through the Neuropace RNS (responsive neurostimulation) system at settings to maximally reduce tic frequency \& severity, while limiting potential stimulation-induced side-effects.

* There will be a one month post-operative period during which stimulation is not turned on.
* One month post-implant, subjects will be randomized one to one in a blinded fashion to receive active or sham stimulation.
* By Day 60, all subjects will be programmed to receive active stimulation. Physiological data will be collected for Specific Aim 2 of the study.
* Both the sham and the active groups (3 subjects in each group) will undergo identical programming procedures at 30 and 60 days.

Group Type ACTIVE_COMPARATOR

NeuroPace RNS® System Deep Brain Stimulator

Intervention Type DEVICE

Utilizes a signal that the device detects and will respond to with an electrical pre-defined pulse if the signal is encountered.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NeuroPace RNS® System Deep Brain Stimulator

Utilizes a signal that the device detects and will respond to with an electrical pre-defined pulse if the signal is encountered.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

NeuroPace DBS (deep brain stimulation)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* diagnosis of TS must be made by both a neurologist and a psychiatrist and must meet standardized criteria
* must have a minimum score on the primary tic rating scale
* symptoms must be causing significant impairment in functioning, making it impossible or almost impossible to do daily activities, including work or school and interactions with friends and family, causing severe distress and a poor quality of life
* symptoms have not responded well enough to medications prescribed by a neurologist or psychiatrist experienced in treating TS. Must have had trials of drugs from three different classes of drugs that have not worked.
* must have received stable and effective treatment of any other existing medical or psychological problems for the past 6 months.
* current TS related-medication(s) must be stable for at least a month without a dose change prior to surgery and must be willing to keep these medications stable and unchanged throughout the study or must be off of TS-related medications for at least three months prior to surgery
* If tics involve only one group of muscles or might be controllable by botulinum toxin treatment, must try botulinum treatment before considering surgery.
* must have a negative urine drug screen
* must give informed consent

Exclusion Criteria

* have a simple motor tic or movement disorder other than TS, or medication-related movement disorders from TS medications
* have had any previous brain surgery including deep brain stimulation, ablative capsulotomy or cingulotomy
* have another psychiatric condition (including body dysmorphic disorder, a delusional disorder or a biological brain disorder), dementia or cognitive dysfunction that would place subject at risk for worsening cognition and/or may impact ability to comply with study procedures. Also included is any other psychiatric disorder that requires medications or treatments that would interfere with the functioning of the DBS device.
* have any significant substance abuse or dependence (e.g., stimulants, alcohol, opiates, benzodiazepines) within the past six months
* have a severe medical disease including cardiovascular disorder, lung disorder, kidney disease, chronic neurological disease, hematological disease, or frailty that impacts tolerability of the surgery as judged by the screening physicians
* pre-surgery MRI is considered abnormal. You may also be excluded if your brain is considered very small.
* have a history of serious suicidal behavior, are unable to control suicide attempts, or are currently at risk of suicide, in the judgement of the investigator
* have head-banging tics or tics that have the potential to damage the RNS System
* are currently pregnant or breast-feeding, plan to become pregnant during the study, or are not using effective contraception
* are currently enrolled in another investigational study
* have an implant such as a pacemaker or neurostimulator containing electrical circuitry or that generates electrical signals
* have any metal orthopedic pins or plates, metal orthodontics, or non-removable body jewelry
* require diathermy treatments during physical or occupational therapy
* have a problem that will require repeat Magnetic Resonance Imaging (MRI) scans
Minimum Eligible Age

25 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Florida

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michael Okun, MD

Role: PRINCIPAL_INVESTIGATOR

University of Florida

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Florida Movement Disorders Center

Gainesville, Florida, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Okun MS, Foote KD, Wu SS, Ward HE, Bowers D, Rodriguez RL, Malaty IA, Goodman WK, Gilbert DM, Walker HC, Mink JW, Merritt S, Morishita T, Sanchez JC. A trial of scheduled deep brain stimulation for Tourette syndrome: moving away from continuous deep brain stimulation paradigms. JAMA Neurol. 2013 Jan;70(1):85-94. doi: 10.1001/jamaneurol.2013.580.

Reference Type DERIVED
PMID: 23044532 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3435399/

Increased Thalamic Gamma Band Activity Correlates with Symptom Relief following Deep Brain Stimulation in Humans with Tourette's Syndrome

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

414-2008- A

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

tDCS in Tourette (TIC-TDCS)
NCT03401996 UNKNOWN NA
Median Nerve Stimulation Pilot
NCT04731714 COMPLETED NA